Applied Industrial (NYSE:AIT) Delivers Impressive Q2 CY2026
Applied Industrial (NYSE: AIT) reported Q2 CY2026 revenue of $1.35 billion, up 10.4% year over year and 4.6% above Wall Street estimates, according to the company. GAAP EPS was $3.17, up from $2.80, beating consensus by 8.7%. Analysts expect revenue growth of 4.4% and full-year EPS to rise from $10.96 to $11.76.
How this was made

The 30-second read
Why it matters
Traders can use the reported beat and the modest forward revenue growth expectation to gauge whether the market will reward the quarter or refocus on slower top-line momentum.
Market read
Q2 beat on revenue and EPS with stable operating margin, but organic revenue flat and forward revenue growth only modest.
What to watch
Operating margin stability is noted, but the forward revenue growth expectation (4.4%) suggests limited incremental upside unless margins or organic growth re-accelerate.
Background
The piece frames Applied Industrial’s Q2 CY2026 results versus Wall Street expectations and discusses longer-term revenue and EPS trends.
Ticker impact
Applied Industrial reported Q2 CY2026 revenue of $1.35B (+10.4% YoY) and GAAP EPS $3.17, beating consensus by 8.7%.
Likely supports a positive bias versus pre-earnings expectations, but upside may be capped if traders focus on the 12-month revenue growth outlook of 4.4%.
The article provides concrete Q2 results (revenue, EPS, beat vs estimates) and a forward-looking consensus revenue growth rate, which can drive post-earnings positioning and revisions.
Market effects
Signals resilience in industrial distribution demand, though organic revenue was described as flat over two years.
No specific regional demand or macro linkage provided.
No explicit international exposure or FX sensitivity details beyond organic vs headline framing.
Counterpoint
The headline beat may be driven by acquisitions and foreign exchange, while organic revenue was flat over two years, implying underlying demand is not accelerating.
Key entities
- companyApplied Industrial
Industrial products distributor reporting Q2 CY2026 revenue and GAAP EPS, plus forward consensus growth expectations.


